Bayer HealthCare reports oncology data at ESMO 2012

Bayer HealthCare is reporting new clinical data on a number of key cancer compounds at the European Society for Medical Oncology (ESMO) congress in Vienna at the end of the month.

The company will be sharing phase III clinical trial data for investigational therapies such as regorafenib, with results from the Correct trial showing its performance as a treatment for metastatic colorectal cancer.

Meanwhile, survival, quality of life and safety data for the new drug radium-223 dichloride will illustrate the compound's potential benefits against castration-resistant prostate cancer.

Additionally, the approved therapy Nexavar will be discussed as a non-small cell lung cancer therapy, while trial data will also highlight its potential efficacy in combination with Tarceva against liver cancer.

Dr Kemal Malik, member of the Bayer HealthCare executive committee and head of global development, said: "This data will provide greater insight into the potential use of these investigational treatments for physicians and patients across multiple tumour types and stages of disease."

Last month, the company reported trial data for the drug Xarelto, showing its efficacy among acute coronary syndrome patients.